Pfizer (PFE) Competitors $26.36 +0.59 (+2.29%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPNShould you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry. Pfizer vs. Johnson & Johnson AbbVie Merck & Co., Inc. Bristol-Myers Squibb Zoetis Royalty Pharma Jazz Pharmaceuticals Corcept Therapeutics Perrigo Supernus Pharmaceuticals Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Does the MarketBeat Community favor JNJ or PFE? Pfizer received 393 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.03% of users gave Pfizer an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote. CompanyUnderperformOutperformJohnson & JohnsonOutperform Votes111465.15% Underperform Votes59634.85% PfizerOutperform Votes150769.03% Underperform Votes67630.97% Is JNJ or PFE more profitable? Johnson & Johnson has a net margin of 19.14% compared to Pfizer's net margin of 7.07%. Johnson & Johnson's return on equity of 35.45% beat Pfizer's return on equity.Company Net Margins Return on Equity Return on Assets Johnson & Johnson19.14% 35.45% 14.23% Pfizer 7.07%16.28%6.68% Is JNJ or PFE a better dividend stock? Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.5%. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Pfizer pays out 232.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 63 consecutive years and Pfizer has increased its dividend for 15 consecutive years. Do analysts recommend JNJ or PFE? Johnson & Johnson currently has a consensus price target of $174.73, indicating a potential upside of 20.95%. Pfizer has a consensus price target of $32.14, indicating a potential upside of 21.94%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Johnson & Johnson 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Pfizer 1 Sell rating(s) 9 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.47 Does the media prefer JNJ or PFE? In the previous week, Pfizer had 54 more articles in the media than Johnson & Johnson. MarketBeat recorded 73 mentions for Pfizer and 19 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.93 beat Pfizer's score of 0.47 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Pfizer 22 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Which has stronger earnings & valuation, JNJ or PFE? Johnson & Johnson has higher revenue and earnings than Pfizer. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJohnson & Johnson$87.70B3.97$35.15B$6.9120.91Pfizer$59.38B2.52$2.12B$0.7435.62 Do institutionals and insiders have more ownership in JNJ or PFE? 69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, JNJ or PFE? Johnson & Johnson has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. SummaryJohnson & Johnson beats Pfizer on 14 of the 22 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFE vs. The Competition Export to ExcelMetricPfizerPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$149.38B$6.57B$5.01B$19.19BDividend Yield6.65%3.09%4.87%3.58%P/E Ratio35.6210.55135.0741.22Price / Sales2.52195.041,120.6317.58Price / Cash8.5957.1640.5821.28Price / Book1.675.104.755.32Net Income$2.12B$151.51M$118.50M$989.67M7 Day Performance3.05%-2.13%-1.85%-3.45%1 Month Performance5.18%-3.13%11.28%-3.73%1 Year Performance-6.87%11.54%29.92%12.06% Pfizer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFEPfizer4.9831 of 5 stars$26.36+2.3%$32.14+21.9%-4.6%$149.38B$59.38B35.6288,000Analyst ForecastOptions VolumeAnalyst RevisionHigh Trading VolumeJNJJohnson & Johnson4.8925 of 5 stars$145.16-1.0%$174.73+20.4%-5.7%$349.49B$87.70B21.22131,900ABBVAbbVie4.9353 of 5 stars$172.15-0.7%$203.65+18.3%+15.7%$304.21B$55.53B60.2350,000Analyst ForecastInsider TradeMRKMerck & Co., Inc.4.989 of 5 stars$100.84-0.3%$129.20+28.1%-6.9%$255.09B$60.12B21.3172,000Analyst DowngradeBMYBristol-Myers Squibb4.7866 of 5 stars$56.27+0.9%$55.64-1.1%+12.5%$114.13B$47.44B-15.5434,100ZTSZoetis4.6049 of 5 stars$177.22-0.5%$216.70+22.3%-15.3%$79.96B$8.54B33.4914,100RPRXRoyalty Pharma4.6273 of 5 stars$25.18+1.4%$41.67+65.5%-7.9%$14.84B$2.36B12.8780JAZZJazz Pharmaceuticals4.8483 of 5 stars$124.76+1.4%$177.00+41.9%+2.7%$7.54B$3.99B17.332,800CORTCorcept Therapeutics4.9101 of 5 stars$55.54+0.3%$65.25+17.5%+66.5%$5.82B$482.38M43.97300Analyst RevisionPRGOPerrigo4.986 of 5 stars$26.88-2.1%$37.00+37.6%-16.6%$3.67B$4.66B-23.469,140Positive NewsSUPNSupernus Pharmaceuticals2.5074 of 5 stars$36.96+2.2%$36.00-2.6%+29.2%$2.04B$651.97M33.91580 Related Companies and Tools Related Companies Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Jazz Pharmaceuticals Alternatives Corcept Therapeutics Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PFE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PFE Stock Alerts